Comparable Efficacy and Safety of Insulin Glulisine and Insulin Lispro When Given as Part of a Basal–Bolus Insulin Regimen in a 26-Week Trial in Pediatric Patients with Type 1 Diabetes-Reference-Cited by-同舟云学术

Comparable Efficacy and Safety of Insulin Glulisine and Insulin Lispro When Given as Part of a Basal–Bolus Insulin Regimen in a 26-Week Trial in Pediatric Patients with Type 1 Diabetes

Published:2011-03 Issue:3 Volume:13 Page:327-334
ISSN:1520-9156
Container-title:Diabetes Technology & Therapeutics
language:en
Short-container-title:Diabetes Technology & Therapeutics

Author:

Philotheou Areti¹,Arslanian Silva²,Blatniczky László³,Peterkova Valentina⁴,Souhami Elisabeth⁵,Danne Thomas⁶

Affiliation:

1. University of Cape Town Diabetes Clinical Trials Unit, New Groote Schuur Hospital, Cape Town, South Africa.

2. Divisions of Pediatric Endocrinology, Metabolism and Diabetes Mellitus, and Weight Management and Wellness, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

3. Buda Children's Hospital, Budapest, Hungary.

4. Endocrinological Scientific Centre, Russian Academy of Science, Moscow, Russia.

5. Sanofi-aventis, Antony, France.

6. Children's Hospital auf der Bult, Hannover, Germany.

Publisher

Mary Ann Liebert Inc

Subject

Medical Laboratory Technology,Endocrinology,Endocrinology, Diabetes and Metabolism

Link

http://www.liebertpub.com/doi/pdf/10.1089/dia.2010.0072

Reference31 articles.

1. New developments in the treatment of type 1 diabetes in children